Prefrontal cortical thickness and clinical characteristics of long-term treatment response to valproate in bipolar disorder

Rodríguez-Ramírez, Alejandra Monserrat; Cedillo-Ríos, Valente; Becerra‐Palars, Claudia; Meza-Urzúa, Fátima; Jiménez-Pavón, Joanna; Morales-Cedillo, Pamela; López-Titla, María Margarita; Sánchez-Segura, César Leonardo; Martínez-Gudiño, Maria de Lourdes; Ortega‐Ortiz, Hiram; Camarena-Medellín, Beatriz

doi:10.1016/j.pscychresns.2021.111382

Cited by 2 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results from the comparative analysis between groups reported a higher median of mixed episodes in the FR group, which is in line with previous findings in BD patients showing a link between mixed episodes and valproate response (Cipriani et al, 2013;Novák et al, 2011;Swann et al, 2002). Bowden (1995) In this study, we replicated previous reports of cortical thickening in patients with FR to valproate (Rodríguez-Ramírez et al, 2021).…”

Section: Discussionsupporting

confidence: 92%

“…In this study, we replicated previous reports of cortical thickening in patients with FR to valproate (Rodríguez‐Ramírez et al, 2021). These findings can be explained by the effects of valproate over the gray matter (GM) or patients' preexisting brain structural characteristics.…”

Section: Discussionsupporting

confidence: 92%

“…Bowden (1995) and Freeman et al (1992) reported a higher frequency of treatment response to valproate in patients with mixed mania. Also, a previous study associated the history of mixed features with increased odds of achieving a full LTTR to valproate (Rodríguez‐Ramírez et al, 2021). On the other hand, other studies had different findings.…”

Section: Discussionmentioning

confidence: 95%

“…The scale created by Grof, Duffy, Cavazzoni, Grof, et al (2002) has been used in many genetic studies to define full responders as subjects with remission for all or most of the treatment time. A recent publication associated the cortical thickness of the dorsolateral prefrontal cortex (dlPFC) with LTTR to valproate, suggesting better preservation of cortical structure in patients with a full response to this medication (Rodríguez‐Ramírez et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

“…valproate(Rodríguez-Ramírez et al, 2021). On the other hand, other studies had different findings Ahn et al (2017).…”

mentioning

confidence: 97%

See 4 more Smart Citations

Association of BDNF risk variant and dorsolateral cortical thickness with long‐term treatment response to valproate in type I bipolar disorder: An exploratory study

Rodríguez‐Ramírez,

Cedillo‐Ríos,

Sanabrais‐Jiménez

et al. 2023

American J of Med Genetics Pt B

View full text Add to dashboard Cite

Valproate is among the most prescribed drugs for bipolar disorder; however, 87% of patients do not report full long‐term treatment response (LTTR) to this medication. One of valproate's suggested mechanisms of action involves the brain‐derived neurotrophic factor (BDNF), expressed in the brain areas regulating emotions, such as the prefrontal cortex. Nonetheless, data about the role of BDNF in LTTR and its implications in the structure of the dorsolateral prefrontal cortex (dlPFC) is scarce. We explore the association of BDNF variants and dorsolateral cortical thickness (CT) with LTTR to valproate in bipolar disorder type I (BDI). Twenty‐eight BDI patients were genotyped for BDNF polymorphisms rs1519480, rs6265, and rs7124442, and T1‐weighted 3D brain scans were acquired. LTTR to valproate was evaluated with Alda's scale. A logistic regression analysis was conducted to evaluate LTTR according to BDNF genotypes and CT. We evaluated CT differences by genotypes with analysis of covariance. LTTR was associated with BDNF rs1519480 and right dlPFC thickness. Insufficient responders with the CC genotype had thicker right dlPFC than TC and TT genotypes. Full responders reported thicker right dlPFC in TC and TT genotypes. In conclusion, different patterns of CT related to BDNF genotypes were identified, suggesting a potential biomarker of LTTR to valproate in our population.

show abstract